A placebo controlled, double-blind evaluation of levamisole in the reduction of the frequency, duration and severity of attacks in children suffering from recurrent upper respiratory tract infections.
In a double-blind placebo controlled study of levamisole in the treatment of children with recurrent upper respiratory tract infection (URI) eighty-six patients took part. Medication was given once a week, in a single body-weight adjusted dose. The children treated with levamisole had a statistically significantly reduced incidence of episodes of infection which were severe, less prolonged and required less antibiotics. No side-effects were reported.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D011446:Prospective Studies; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000453:epidemiology; D013997:Time Factors
D010919:Placebos; D007978:Levamisole